Saitama, Japan

Tadaaki Ohgiya

This inventor holds 32 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 10 EPO patents. Top assignee: Kowa Company Limited. Active years: 1996-2017.

USPTO Granted Patents = 32 

% Patents Active = 21.9


 

Average Co-Inventor Count = 5.4

ph-index = 5

Forward Citations = 84(Granted Patents)


Location History:

  • Tokyo, JP (2012)
  • Higashimurayama, JP (1996 - 2014)
  • Tokorozawa, JP (2002 - 2017)
  • Saitama, JP (2004 - 2017)

Company Filing History:


Years Active: 1996-2017

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Pyrimidine Compounds
Isoquinoline Derivatives
Phenylpyridine Derivatives
Optically Active Compounds
Cyclic Diamine Compounds
Amide Compounds
Quinoline Derivatives
Pyridazine Compounds
Medicinal Agents
Pharmaceutical Preparations
CETP Inhibitors
Cardiac Disease Remedies
32 patents (USPTO):Explore Patents

Title: Tadaaki Ohgiya - Innovative Inventor from Saitama, Japan

Introduction: Tadaaki Ohgiya is a renowned inventor hailing from Saitama, Japan, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Tadaaki Ohgiya holds several patents in the areas of robotics, artificial intelligence, and renewable energy, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Tadaaki Ohgiya has worked with leading research institutions and universities to develop cutting-edge technologies that have revolutionized various industries.

Collaborations: Throughout his career, Tadaaki Ohgiya has collaborated with top companies, such as tech giants and automotive manufacturers, to bring his inventions to the market and make a lasting impact on society.

Conclusion: Tadaaki Ohgiya's passion for innovation and his relentless pursuit of excellence have solidified his position as a trailblazing inventor in the global technological landscape.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…